timothy sykes logo
BTSG Surges As BrightSpring Lifts 2026 Guidance After Q3 Beat Thumbnail
G Google News

BTSG Surges As BrightSpring Lifts 2026 Guidance After Q3 Beat

JACK KELLOGG•UPDATED OCT. 31, 2026, 10:07 AM ET
Reviewed by Tim Sykesand Fact-checked by Ellis Hobbs

BrightSpring Health Services Inc. shares surged as positive coverage drove buying interest, with stocks have been trading up by 10.92 percent.

What Traders Need To Know

  • Strong Q3 2026 print showed 26% revenue growth and 42% Adjusted EBITDA growth, with net income from continuing operations nearly tripling and leverage cut to 1.79x.
  • Core Q3 revenue of $4.21B smashed the $3.88B Street estimate, while adjusted EPS of $0.54 topped the $0.47 consensus despite a $0.01 GAAP EPS miss.
  • Management raised FY26 revenue guidance to $15.9B-$16.125B and lifted FY26 Adjusted EBITDA to $850M-$860M, well ahead of prior outlook and Street expectations.
  • Recently acquired Amedisys and LHC branches are contributing to higher 2026 revenue and EBITDA guidance, reinforcing the M&A-driven growth story.
  • Shares jumped about 8% in premarket trading after the beat-and-raise Q3, signaling a bullish shift in sentiment toward BTSG.

Candlestick Chart

Weekly Update Oct 26 – Oct 30, 2026: On Saturday, October 31, 2026 BrightSpring Health Services Inc. stock [NASDAQ: BTSG] is trending up by 10.92%! Discover the key drivers behind this movement as well as our expert analysis in the detailed breakdown below.

Healthcare industry expert:

Analyst sentiment – positive

BrightSpring (BTSG) is emerging as a scaled provider in home- and community‑based care and pharmacy services, but its fundamentals still look early‑cycle public company rather than mature compounder. Q3 revenue annualizes near the $16B guidance, confirming rapid growth, yet margins remain thin: EBIT margin ~2.5%, EBITDA margin 3.7%, and gross margin 12.4%. Valuation is demanding at ~0.9x sales and ~39x EPS with a very high ~72x cash‑flow multiple, despite leverage of 1.8–2.9x and meaningful goodwill intensity.

Technically, the stock has broken sharply higher, moving from ~58 to ~67 in a week, with a strong expansion day on 10/30 (gap‑up and close near the high), confirming a short‑term bullish trend. Intraday 5‑minute candles show persistent buying on elevated volume, not just a one‑print spike, suggesting real accumulation. First actionable level is support near $60–61, the prior breakout zone and VWAP area from the gap day; risk‑defined long entries above $61 with stops around $58 look justified while momentum persists.

Fundamentally, Q3 delivered 26% revenue growth, 42% adjusted EBITDA growth, and a near tripling in continuing net income, plus raised 2026 revenue and EBITDA guidance above Street, driven by Amedisys/LHC consolidation and strong core execution. This growth and deleveraging trajectory screens better than the broader Healthcare and Providers & Services groups, albeit with structurally lower margins and higher valuation. I see continued re‑rating potential, with near‑term resistance around $70 and a 6‑12 month upside target of $78.

More Breaking News

Quick Financial Overview

BrightSpring Health Services Inc. just printed the kind of quarter that typically attracts momentum. Q3 2026 revenue reached $4.21B versus roughly $3.88B expected, a 26% year-over-year gain backed by Pharmacy and Provider strength. Adjusted EBITDA grew 42%, with net income from continuing operations nearly tripling and profit margin from continuing operations at 1.73%. For a business doing roughly $12.9B in trailing revenue, that kind of earnings acceleration matters.

On valuation, BTSG trades at a price-to-sales ratio of 0.88 and a P/E of 38.63. Margins are still thin, with EBIT margin at 2.5% and EBITDA margin at 3.7%, but they are moving in the right direction. Return on equity above 19% on an LTM basis and an asset turnover of 2.4 show the company is squeezing solid efficiency out of its asset base. With enterprise value around $14.90B, the market is clearly starting to price in sustained growth and improving profitability.

The balance sheet is better than many high-growth healthcare names. Total debt-to-equity is 1.17 with leverage at 2.9, while current and quick ratios of 1.6 and 1.1 suggest near-term liquidity is manageable. Q3 operating cash flow of about $204.3M and free cash flow of $182.2M back up the story of “robust cash generation” from management. Leverage reduction to 1.79x, plus $717.8M in cash, gives BrightSpring Health Services Inc. room to keep integrating Amedisys and LHC and possibly pursue more targeted deals.

On the tape, BTSG is acting like a classic earnings-breakout name. The weekly data show the stock grinding from the high-$50s to a close near $66.80 by 2026/10/30, with a big expansion bar on the last day of the week. Intraday, the 5-minute snapshot shows a surge from an open around $65.29 to a spike near $71.12 before settling back around $66.89. That pattern tells you there was aggressive buying on the news, followed by some profit taking but with bulls still in control into the close.

Conclusion

This is stock news, not investment advice. Timothy Sykes News delivers real-time stock market news focused on key catalysts driving short-term price movements. Our content is tailored for active traders and investors seeking to capitalize on rapid price fluctuations, particularly in volatile sectors like penny stocks. Readers come to us for detailed coverage on earnings reports, mergers, FDA approvals, new contracts, and unusual trading volumes that can trigger significant short-term price action. Some users utilize our news to explain sudden stock movements, while others rely on it for diligent research into potential investment opportunities.

Dive deeper into the world of trading with Timothy Sykes, renowned for his expertise in penny stocks. Explore his top picks and discover the strategies that have propelled him to success with these articles:

Once you’ve got some stocks on watch, elevate your trading game with StocksToTrade the ultimate platform for traders. With specialized tools for swing and day trading, StocksToTrade will guide you through the market’s twists and turns.
Dig into StocksToTrade’s watchlists here:

How much has this post helped you?

(0 votes, average: 0 out of 5)
Leave a reply

* Results are not typical and will vary from person to person. Making money trading stocks takes time, dedication, and hard work. There are inherent risks involved with investing in the stock market, including the loss of your investment. Past performance in the market is not indicative of future results. Any investment is at your own risk. See Terms of Service here

The available research on day trading suggests that most active traders lose money. Fees and overtrading are major contributors to these losses.

A 2000 study called “Trading is Hazardous to Your Wealth: The Common Stock Investment Performance of Individual Investors” evaluated 66,465 U.S. households that held stocks from 1991 to 1996. The households that traded most averaged an 11.4% annual return during a period where the overall market gained 17.9%. These lower returns were attributed to overconfidence.

A 2014 paper (revised 2019) titled “Learning Fast or Slow?” analyzed the complete transaction history of the Taiwan Stock Exchange between 1992 and 2006. It looked at the ongoing performance of day traders in this sample, and found that 97% of day traders can expect to lose money from trading, and more than 90% of all day trading volume can be traced to investors who predictably lose money. Additionally, it tied the behavior of gamblers and drivers who get more speeding tickets to overtrading, and cited studies showing that legalized gambling has an inverse effect on trading volume.

A 2019 research study (revised 2020) called “Day Trading for a Living?” observed 19,646 Brazilian futures contract traders who started day trading from 2013 to 2015, and recorded two years of their trading activity. The study authors found that 97% of traders with more than 300 days actively trading lost money, and only 1.1% earned more than the Brazilian minimum wage ($16 USD per day). They hypothesized that the greater returns shown in previous studies did not differentiate between frequent day traders and those who traded rarely, and that more frequent trading activity decreases the chance of profitability.

These studies show the wide variance of the available data on day trading profitability. One thing that seems clear from the research is that most day traders lose money .

Millionaire Media 66 W Flagler St. Ste. 900 Miami, FL 33130 United States (888) 878-3621 This is for information purposes only as Millionaire Media LLC nor Timothy Sykes is registered as a securities broker-dealer or an investment adviser. No information herein is intended as securities brokerage, investment, tax, accounting or legal advice, as an offer or solicitation of an offer to sell or buy, or as an endorsement, recommendation or sponsorship of any company, security or fund. Millionaire Media LLC and Timothy Sykes cannot and does not assess, verify or guarantee the adequacy, accuracy or completeness of any information, the suitability or profitability of any particular investment, or the potential value of any investment or informational source. The reader bears responsibility for his/her own investment research and decisions, should seek the advice of a qualified securities professional before making any investment, and investigate and fully understand any and all risks before investing. Millionaire Media LLC and Timothy Sykes in no way warrants the solvency, financial condition, or investment advisability of any of the securities mentioned in communications or websites. In addition, Millionaire Media LLC and Timothy Sykes accepts no liability whatsoever for any direct or consequential loss arising from any use of this information. This information is not intended to be used as the sole basis of any investment decision, nor should it be construed as advice designed to meet the investment needs of any particular investor. Past performance is not necessarily indicative of future returns.

Citations for Disclaimer

Barber, Brad M. and Odean, Terrance, Trading is Hazardous to Your Wealth: The Common Stock Investment Performance of Individual Investors. Available at SSRN: “Day Trading for a Living?”

Barber, Brad M. and Lee, Yi-Tsung and Liu, Yu-Jane and Odean, Terrance and Zhang, Ke, Learning Fast or Slow? (May 28, 2019). Forthcoming: Review of Asset Pricing Studies, Available at SSRN: “https://ssrn.com/abstract=2535636”

Chague, Fernando and De-Losso, Rodrigo and Giovannetti, Bruno, Day Trading for a Living? (June 11, 2020). Available at SSRN: “https://ssrn.com/abstract=3423101”